Prestige BioPharma Limited (KRX:950210)

Market Cap	177.52B
Revenue (ttm)	8.66B
Net Income (ttm)	21.79B
Shares Out	12.02M
EPS (ttm)	361.82
PE Ratio	40.82
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,026
Average Volume	165,762
Open	14,540
Previous Close	14,540
Day's Range	14,390 - 15,000
52-Week Range	11,000 - 20,900
Beta	1.10
RSI	53.47
Earnings Date	Sep 19, 2025

About Prestige BioPharma

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Country: Singapore
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 950210